f Advances in Gene Therapy for X-Linked Myotubular Myopathy: Current Progress and Future Challenges

References

1. Barreto-Mota R. Figueirinha J. Quental R. X-linked myotubular myopathy: A clinical report and a review of the mild phenotype. Rev. Neurol. 2023 76 7 243 246 36973888
   [Google Scholar]
2. Giraud Q. Spiegelhalter C. Messaddeq N. Laporte J. MTM1 overexpression prevents and reverts BIN1-related centronuclear myopathy. Brain 2023 146 10 4158 4173 10.1093/brain/awad251 37490306
   [Google Scholar]
3. Gómez-Oca R. Cowling B.S. Laporte J. Common pathogenic mechanisms in centronuclear and myotubular myopathies and latest treatment advances. Int. J. Mol. Sci. 2021 22 21 11377 10.3390/ijms222111377 34768808
   [Google Scholar]
4. Annoussamy M. Lilien C. Gidaro T. X-linked myotubular myopathy. Neurology 2019 92 16 e1852 e1867 10.1212/WNL.0000000000007319 30902907
   [Google Scholar]
5. Shieh P. Kuntz N. Dowling J. Müller-Felber W. Bönnemann C. Foley D. OP018: ASPIRO gene therapy trial in X-linked myotubular myopathy (XLMTM): Update on preliminary efficacy and safety findings. Genet. Med. 2022 24 3 Suppl. S350 10.1016/j.gim.2022.01.568
   [Google Scholar]
6. Karolczak S. Deshwar A.R. Aristegui E. Loss of Mtm1 causes cholestatic liver disease in a model of X-linked myotubular myopathy. J. Clin. Invest. 2023 133 18 e166275 10.1172/JCI166275 37490339
   [Google Scholar]
7. Kirk K. Kuntz N. Shieh P. Coats J. Han C. Miller W. Long term preliminary safety and efficacy outcomes for x-linked myotubular myopathy with gene replacement therapy. Arq. Neuropsiquiatr. 2023 81 A009
   [Google Scholar]
8. Qie B. Tuo J. Chen F. Ding H. Lyu L. Gene therapy for genetic diseases: Challenges and future directions. MedComm 2025 6 2 e70091 10.1002/mco2.70091 39949979
   [Google Scholar]